Policy Statement

Gastric electrical stimulation is considered investigational for the treatment of gastroparesis of diabetic, idiopathic, or postsurgical etiology.

Gastric electrical stimulation is considered investigational for the treatment of obesity.

Policy Guidelines

There are CPT codes specific to insertion of the gastric stimulation device:

- **43647**: Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
- **43648**: Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
- **43881**: Implantation or replacement of gastric neurostimulator electrodes, antrum, open
- **43882**: Revision or removal of gastric neurostimulator electrodes, antrum, open
- **64590**: Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
- **64595**: Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver

There are also specific codes for electronic analysis and programming of gastric neurostimulator pulse generator:

- **95980**: Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming
- **95981**: Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming
- **95982**: Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming

The following HCPCS codes may be used:

- **L8680**: Implantable neurostimulator electrode, each (implant requires 2 leads)
- **L8685**: Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
- **L8686**: Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
- **L8687**: Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
- **L8688**: Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
### Description

Gastric electrical stimulation (GES) is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastroparesis of diabetic, idiopathic, or postsurgical etiology. GES has also been investigated as a treatment of obesity. The device may be referred to as a gastric pacemaker.

### Related Policies

- Vagus Nerve Blocking Therapy for Treatment of Obesity
- Vagus Nerve Stimulation

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

In 2000, the Gastric Electrical Stimulator system (now called Enterra™ Therapy System; Medtronic) was approved by the U.S. Food and Drug Administration through the humanitarian device exemption process (H990014) for the treatment of gastroparesis. The GES system consists of 4 components: the implanted pulse generator, 2 unipolar intra muscular stomach leads, the stimulator programmer, and the memory cartridge. With the exception of the intramuscular leads, all other components have been used in other implantable neurologic stimulators, such as spinal cord or sacral nerve stimulation. The intramuscular stomach leads are implanted either laparoscopically or during laparotomy and are connected to the pulse generator, which is implanted in a subcutaneous pocket. The programmer sets the stimulation parameters, which are typically set at a “on” time of 0.1 seconds alternating with an “off” time of 5.0 seconds.

Currently, no GES devices have been approved by the Food and Drug Administration for the treatment of obesity. The Transcend® (Transneuronix; acquired by Medtronic in 2005), an implantable gastric stimulation device, is available in Europe for treatment of obesity.

### Rationale

#### Background

**Gastroparesis**

Gastroparesis is a chronic disorder of gastric motility characterized by delayed emptying of a solid meal. Symptoms include bloating, distension, nausea, and vomiting. When severe and chronic, gastroparesis can be associated with dehydration, poor nutritional status, and poor glycemic control in diabetic patients. While most commonly associated with diabetes, gastroparesis is also found in chronic pseudo-obstruction, connective tissue disorders, Parkinson disease, and psychological pathologic conditions. Some cases may not be associated with an identifiable cause and are referred to as idiopathic gastroparesis. Treatment of gastroparesis...
includes prokinetic agents (e.g., metoclopramide) and antiemetic agents (e.g., metoclopramide, granisetron, ondansetron). Severe cases may require enteral or total parenteral nutrition.

**Treatment**

Gastric electrical stimulation (GES), also referred to as gastric pacing, using an implantable device, has been investigated primarily as a treatment for gastroparesis. Currently available devices consist of a pulse generator, which can be programmed to provide electrical stimulation at different frequencies, connected to intramuscular stomach leads, which are implanted during laparoscopy or open laparotomy (see Regulatory Status section).

**Obesity**

GES has also been investigated as a treatment of obesity. It is used to increase a feeling of satiety with subsequent reduction in food intake and weight loss. The exact mechanisms resulting in changes in eating behavior are uncertain but may be related to neurohormonal modulation and/or stomach muscle stimulation.

**Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice. The following is a summary of the key literature to date.

**Gastric Electrical Stimulation for Gastroparesis**

**Clinical Context and Test Purpose**

The purpose of gastric electrical stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as conservation management, medication, and enteral or total parenteral nutrition, in patients with gastroparesis.

The question addressed in this evidence review is: does gastric electrical stimulation improve the net health outcome for patients with gastroparesis?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with gastroparesis.

**Interventions**

The therapy being considered is gastric electrical stimulation.
Comparators
Comparators of interest include conservative management, medication, enteral or total parenteral nutrition. Treatment includes diet modification and gut motility stimulation.

Outcomes
The general outcomes of interest are symptoms and treatment-related morbidity.

Timing
The existing literature evaluating gastric electrical stimulation as a treatment for gastroparesis has varying lengths of follow up, ranging from 6 to 12 months. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 10 years of follow-up is considered necessary to demonstrate efficacy.

Setting
Patients with gastroparesis are actively managed by a gastroenterologist and primary care provider in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

Systematic Reviews
Several systematic reviews of studies on gastric electrical stimulation (GES) for gastroparesis have been published, the most recent and comprehensive of which is by Levinthal et al (2017). To be selected for the Levinthal review, studies had to include adults with established gastroparesis, report patient symptom scores, and administer treatment for at least 1 week. Five RCTs and 13 non-RCTs meeting criteria were identified. Pooled analysis of data from the 5 RCTs (n=185 patients) did not find a statistically significant difference in symptom severity when the GES was turned on vs off (standardized mean difference [SMD], 0.17; 95% confidence interval [CI], -0.06 to 0.40; p = 0.15). Another pooled analysis did not find a statistically significant difference in nausea severity scores when the GES was on vs off (SMD, -0.143; 95% CI, -0.50 to 0.22; p = 0.45). In a pooled analysis of 13 open-label single-arm studies and data from open-label extensions of 3 RCTs, mean total symptom severity score decreased 2.68 (95% CI, 2.04 to 3.32) at follow-up from a mean of 6.85 (95% CI, 6.28 to 7.42) at baseline. The rate of adverse events in the immediate postoperative period (reported in 7 studies) was 8.7% (95% CI, 4.3% to 17.1%). The in-hospital mortality rate within 30 days of surgery was 1.4% (95% CI, 0.8% to 2.5%), the rate of reoperations (up to 10 years of follow-up) was 11.1% (95% CI, 8.7% to 14.1%), and the rate of device removal was 8.4% (95% CI, 5.7% to 12.2%).

Randomized Controlled Trials
Representative crossover RCTs are described next. Abell et al (2003) reported findings from the Worldwide Anti-Vomiting Electrical Stimulation Study (WAVESS). This double-blind crossover study, initially described in Food and Drug Administration materials, included 33 patients with intractable idiopathic or diabetic gastroparesis. The primary end point was a reduction in vomiting frequency, as measured by patient diaries. In the initial phase of the study, all patients underwent implantation of the stimulator and were randomly and blindly assigned to stimulation on or stimulation off for the first month, with crossover to off and on during the second month. Baseline vomiting frequency was 47 episodes per month, which declined in both on and off groups to 23 to 29 episodes, respectively. However, no statistically significant differences were found in the number of vomiting episodes between groups, suggesting a placebo effect. In the
second, open-label, phase of the trial, all patients had their stimulators turned on for the remainder of the 6- to 12-month follow-up. During this period, vomiting frequency declined in both the idiopathic and diabetic subgroups.

McCallum et al (2010) reported on a crossover RCT evaluating GES (Enterra device) in patients with chronic intractable nausea and vomiting from diabetic gastroparesis. In this trial, 55 patients with refractory diabetic gastroparesis (5.9 years of diabetic gastroparesis) were given Enterra implants. After surgery, all patients had the stimulator turned on for 6 weeks and then were randomized to groups that had consecutive 3-month crossover periods with the device on or off. After this period, the device was turned on in all patients, and they were followed unblinded for 4.5 months. During the initial 6-week phase with the stimulator turned on, the median reduction in weekly vomiting frequency (WVF) compared with baseline was 57%. There was no significant difference in WVF between patients who had the device turned on or off during the 3-month crossover period. At 1 year, the WVF for all patients was significantly lower than baseline values (median reduction, 68%; p < 0.001). One patient had the device removed due to infection; two required surgical intervention for lead-related problems.

McCallum et al (2013) evaluated GES (Enterra system) in patients with chronic vomiting due to idiopathic gastroparesis in a randomized, double-blind crossover trial. In this trial, 32 patients with nausea and vomiting associated with idiopathic gastroparesis, unresponsive or intolerant to prokinetic and antiemetic drugs, received Enterra implants and had the device turned on for 6 weeks. Subsequently, 27 of these patients were randomized to have the device turned on or off for 2 consecutive 3-month periods. Twenty-five of these subjects completed the randomized phase; of note, 2 subjects had the device turned on early, 2 subjects had randomization assignment errors, and 1 subject had missing diaries. During the initial 6-week on period, all subjects showed improvements in their WVF, demonstrating a median reduction of 61.2% (5.5 episodes/week) compared with baseline (17.3 episodes/week; p < 0.001). During the on-off crossover phase, subjects demonstrated no significant differences between the on and off phases for the study’s primary end point, median WVF (median, 6.4 in on-phase vs 9.8 in off-phase; p = 1.0). Among the 19 subjects who completed 12 months of follow-up, there was an 87.1% reduction in median WVF (2 episodes/week) compared with baseline (17.3 episodes/week; p < 0.001). Two subjects required surgical intervention for lead migration/dislodgement or neurostimulator migration.

### Table 1. Summary of Key RCT Characteristics

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell (2003)</td>
<td>US, Canada, EU</td>
<td>11</td>
<td>NR</td>
<td>Patients with intractable idiopathic or diabetic gastroparesis (n=33)</td>
<td>GES (stimulation on) GES (stimulation off)</td>
</tr>
<tr>
<td>McCallum (2010)</td>
<td>US</td>
<td>8</td>
<td>2002-2007</td>
<td>Patients with chronic intractable nausea and vomiting from diabetic gastroparesis (n=55)</td>
<td>GES (stimulation on) GES (stimulation off)</td>
</tr>
<tr>
<td>McCallum (2013)</td>
<td>US</td>
<td>8</td>
<td>2002-2008</td>
<td>Patients with chronic vomiting due to idiopathic gastroparesis (n=32)</td>
<td>GES (stimulation on) GES (stimulation off)</td>
</tr>
</tbody>
</table>

RCT: randomized controlled trial.

Reproduction without authorization from Blue Shield of California is prohibited
Table 2. Summary of Key RCT Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Weekly Vomiting Frequency</th>
<th>Total Symptom Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell (2003)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ON</td>
<td>6.8</td>
<td>12.5±1.0</td>
</tr>
<tr>
<td>OFF</td>
<td>13.5</td>
<td>13.9±1.1</td>
</tr>
<tr>
<td>McCallum (2010)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ON</td>
<td>3.81</td>
<td></td>
</tr>
<tr>
<td>OFF</td>
<td>4.25</td>
<td></td>
</tr>
<tr>
<td>P-value</td>
<td>0.215</td>
<td></td>
</tr>
<tr>
<td>McCallum (2013)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ON</td>
<td>6.38</td>
<td></td>
</tr>
<tr>
<td>OFF</td>
<td>9.75</td>
<td></td>
</tr>
<tr>
<td>P-value</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

RCT: randomized controlled trial.

Table 3. Relevance Gaps

<table>
<thead>
<tr>
<th>Study</th>
<th>Populationa</th>
<th>Interventionb</th>
<th>Comparatorc</th>
<th>Outcomesd</th>
<th>Follow-Upd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell (2003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCallum (2010)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCallum (2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.
c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.
d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.
e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 4. Study Design and Conduct Gaps

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocationa</th>
<th>Blindingb</th>
<th>Selective Reportingc</th>
<th>Follow-Upd</th>
<th>Powere</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell (2003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCallum (2010)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCallum (2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

d Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
f Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.
Nonrandomized Studies
Laine et al (2018) published a retrospective, multicenter analysis of patients with severe, medically refractory gastroparesis who received GES. Fourteen patients (11 diabetic, 1 idiopathic, and 2 postoperative) treated in Finland between 2007 and 2015 were included; median follow-up was 3 years. Eight (57.1%) patients experienced marked relief of gastroparesis symptoms, while 3 (21.4%) patients experienced partial relief. There was a median weight gain of 5.1 kg in 11 (78.6%) patients after GES implantation, and, at last possible follow-up, 5 out of 10 (50%) patients were without medication for gastroparesis. The study was limited by its retrospective nature, small population size, and relatively short follow-up time.

Shada et al (2018) published a prospective study of patients with medically refractory gastroparesis who underwent implantation of GES between 2005 and 2016. One hundred nineteen patients (64 diabetic, 55 idiopathic), with mean follow-up of 39.0 ± 32.0 months, were included in the analysis. Before GES placement, operatively placed feeding tubes were present in 22% of diabetic and 17% of idiopathic patients; however, after GES placement, 67% of feeding tubes were removed. Due to a perceived lack of benefit, 8 patients decided to have their GES device removed after a mean time of 36 ± 29 months. Also, there was a significant improvement in GCSI scores for both diabetic (p=0.01) and idiopathic (p=0.003) subgroups at ≥2 years after implantation. The study was limited by its retrospective nature, not all patients being administered the GCSI before GES, and a number of patients being lost to follow-up.

Section Summary: Gastric Electrical Stimulation for Gastroparesis
Two nonrandomized studies and five crossover RCTs have assessed GES for treating gastroparesis. A 2017 meta-analysis of these 5 RCTs did not find a significant benefit of GES on the severity of symptoms associated with gastroparesis. Patients generally reported improved symptoms at follow-up regardless of whether or not the device was turned on, suggesting a placebo effect. For example, there was no significant difference in the on vs off position in symptom severity or nausea severity scores.

GES for Obesity
Clinical Context and Test Purpose
The purpose of gastric electrical stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as conservative management, medication, and bariatric surgery in patients with obesity.

The question addressed in this evidence review is does gastric electrical stimulation improve the net health outcome for patients with obesity?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest are individuals with obesity.

Interventions
The therapy being considered is gastric electrical stimulation.

Comparators
Comparators of interest include conservative management, medication, and bariatric surgery. Treatment includes physical exercise, low carbohydrate dieting, and low-fat dieting.

Outcomes
The general outcomes of interest are change in disease status and treatment-related morbidity.
Timing
The existing literature evaluating gastric electrical stimulation as a treatment for obesity has varying lengths of follow up, ranging from 1 year. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 1 year of follow-up is considered necessary to demonstrate efficacy.

Setting
Patients with obesity are actively managed by nutritionists and primary care providers in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:
   a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
   b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
   c. To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
   d. Studies with duplicative or overlapping populations were excluded.

A single RCT has evaluated the use of GES for treating obesity: the SHAPE trial. Shikora et al (2009) reported on a double-blind RCT that assessed GES obesity. All 190 trial participants received an implantable gastric stimulator and were randomized to have the stimulator turned on or off. All patients were evaluated monthly, participated in support groups, and reduced their dietary intake by 500 kcal/d. At 12-month follow-up, there was no statistically significant difference in excess weight loss between the treatment group (weight loss, 11.8%) and the control group (weight loss, 11.7%) using intention-to-treat analysis (p=0.717).

Small case series and uncontrolled prospective trials (2002-2004) have reported positive outcomes for weight loss and maintenance of weight loss along with minimal complications. However, interpretation of these uncontrolled studies is limited.

Summary of Evidence
For individuals who have gastroparesis who receive GES, the evidence includes RCTs, nonrandomized studies, and systematic reviews. Relevant outcomes are symptoms and treatment-related morbidity. Five crossover RCTs have been published. A 2017 meta-analysis of these 5 RCTs did not find a significant benefit of GES on the severity of symptoms associated with gastroparesis. Patients generally reported improved symptoms at follow-up whether or not the device was turned on, suggesting a placebo effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have obesity who receive GES, the evidence includes an RCT. Relevant outcomes are change in disease status and treatment-related morbidity. The SHAPE trial did not show significant improvement in weight loss using GES compared with sham stimulation. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2015 Input
In response to requests from Blue Cross Blue Shield Association, input was received from 1 specialty society (2 reviewers) and 4 academic centers in 2015. Most respondents agreed
that gastric electrical stimulation (GES) should be considered investigational for gastroparesis. There was a lack of consensus whether GES should be considered medically necessary for any specific indication (e.g., diabetic gastroparesis, idiopathic gastroparesis, gastroparesis of postsurgical etiology). The reviewers were not asked about the use of GES for treatment of obesity.

2009 Input
In response to requests from Blue Cross Blue Shield Association, input was received from 4 academic medical centers (5 reviewers) in 2009. There was strong agreement among reviewers about the limited data for the use of GES to treat diabetic and idiopathic gastroparesis and about the need for randomized controlled trials. There was strong agreement that GES is investigational in the treatment of obesity.

Practice Guidelines and Position Statements
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (2014) has issued guidance on GES for gastroparesis.\(^\text{17}\) The Institute made the following recommendations:

1.1 “Current evidence on the efficacy and safety of gastric electrical stimulation for gastroparesis is adequate to support the use of this procedure with normal arrangements for clinical governance, consent, and audit.

1.2 … clinicians should inform patients considering gastric electrical stimulation for gastroparesis that some patients do not get any benefit from it. They should also give patients detailed written information about the risk of complications, which can be serious, including the need to remove the device.

1.3 Patient selection and follow-up should be done in specialist gastroenterology units with expertise in gastrointestinal motility disorders, and the procedure should only be performed by surgeons working in these units.

American College of Gastroenterology
The American College of Gastroenterology published practice guidelines on the management of gastroparesis in 2013.\(^\text{18}\) The College recommended that:

“GES [gastric electrical stimulation] may be considered for compassionate treatment in patients with refractory symptoms, particularly nausea and vomiting. Symptom severity and gastric emptying have been shown to improve in patients with DG [diabetic gastroparesis], but not in patients with IG [idiopathic gastroparesis] or PSG [post-surgical gastroparesis]. [Conditional recommendation (there is uncertainty about trade-offs), moderate level of evidence (further research would be likely to have an impact on the confidence in the estimate of effect).]”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 5.

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03261531a</td>
<td>Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity</td>
<td>16</td>
<td>Mar 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
\(^a\) Denotes industry-sponsored or cosponsored trial.

Reproduction without authorization from Blue Shield of California is prohibited
References


Documentation for Clinical Review

Please provide the following documentation (if/when requested):
- History and physical including: previous treatment plan and response
- Multidisciplinary evaluation
Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

IE
The following services may be considered investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>43647</td>
<td>Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td></td>
<td>43648</td>
<td>Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td></td>
<td>43881</td>
<td>Implantation or replacement of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td></td>
<td>43882</td>
<td>Revision or removal of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td></td>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td></td>
<td>64595</td>
<td>Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver</td>
</tr>
<tr>
<td></td>
<td>95980</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming</td>
</tr>
<tr>
<td></td>
<td>95981</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming</td>
</tr>
<tr>
<td></td>
<td>95982</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming</td>
</tr>
<tr>
<td>HCPCS</td>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td></td>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>ICD-10 Procedure</td>
<td>0DH60MZ</td>
<td>Insertion of Stimulator Lead into Stomach, Open Approach</td>
</tr>
<tr>
<td></td>
<td>0DH63MZ</td>
<td>Insertion of Stimulator Lead into Stomach, Percutaneous Approach</td>
</tr>
<tr>
<td></td>
<td>0DH64MZ</td>
<td>Insertion of Stimulator Lead into Stomach, Percutaneous Endoscopic Approach</td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/07/2006</td>
<td>New Policy Adoption</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/03/2009</td>
<td>Policy Revision</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>10/29/2010</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>01/06/2012</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/13/2012</td>
<td>Coding Update</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>11/26/2014</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>09/30/2015</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>02/01/2016</td>
<td>Coding update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>03/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2019</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.
Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.